Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe

USA - English

• USA - español
• USA - Français
• USA - Norsk
• USA - Deutsch
• Norge - English

TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi Sankyo) announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe.

The TaNeDS program was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it expanded abroad, opening up to researchers in Germany, Switzerland and Austria, and becoming known as the TaNeDS Global Program. Now, in 2014, it has expanded further across Europe to include all EU member countries. The program is conducted with the aim of realizing Daiichi Sankyo's corporate slogan of "Passion for Innovation. Compassion for Patients.(TM)" through increasing collaborative opportunities with researchers in Europe. U3 Pharma GmbH (headquarters: Munich, Germany; hereafter, U3 Pharma), a wholly owned subsidiary of Daiichi Sankyo, is also participating in the program in order to nurture the seeds of drug discovery for the next generation.

About the TaNeDS Global Programme 2014

(1) Countries where research could be conducted:
    All EU member countries plus Norway and Switzerland.

(2) Overview of research programs
    Daiichi Sankyo seeks innovative technological research collaborators for 
    novel drug discovery and testing projects that could result in novel drug 
    discovery and novel new drugs.

(3) Research themes
    1. Cancer
      New targeted and investigative research for small-molecule and biologic 
      treatments (antibody drugs, etc.).
    2. Cardiovascular and metabolic disorders
      New mechanisms and drug treatments for obesity, kidney and renovascular-
      related disorders.
    3. Other disorders
      New mechanisms and drug treatments for genetic disorders, new drug 
      treatments for pain, genetic analysis and new drug research for rare 
      diseases.
    4. Revolutionary drug discovery technology
      New biologic technology, target molecules and delivery systems for 
      nucleic acid treatments, new technology for drug development based on 
      protein structural analysis.

For more details, please visit the TaNeDS Global Programme page at: http://www.daiichisankyo.com/rd/taneds/index.html

(4) Budget and period of research
    Up to 150,000 euros per year for collaborative research projects lasting 
    up to 2 years.

(5) Eligibility
    Researchers of any nationality employed by universities, research 
    institutes and start-up companies within the EU, as well as Norway and 
    Switzerland, who can conduct research in those countries on projects that 
    match Daiichi Sankyo's desired research themes.

(6) Selection process
    Daiichi Sankyo and U3 Pharma researchers will select research projects 
    that match their research needs as well as demonstrate originality, 
    potential and promise as drug discovery candidates.

(7) Schedule
    Application period:                             October 1 to November 15, 2014
    First shortlist selection period:        Mid-November to mid-December 2014
    Second shortlist selection period:  Mid-December 2014 to early    
                                                                   February 2015
    Start of research programs:             From mid-April 2015

Selection Results for the TaNeDS Global Program 2013

The application process for 2013 resulted in 2 projects being selected and those collaborations are currently underway.

(1) Applications          49
(2) Selected                   2

The two selected laboratories, from the University of Wuertzburg in Germany and the Medical University of Innsbruck in Austria, are both conducting research in the field of cancer therapy.

About Daiichi Sankyo Company, Limited
Representative: Joji Nakayama, Representative Director, President and CEO
(Code No.: 4568, First Section, Tokyo Stock Exchange)

Contact:
Toshiya Kondo
Senior Director, Public Relations Group
Corporate Communications Department
Daiichi Sankyo Company, Limited
Tel: +81-3-6225-1126
[email protected]
http://www.daiichisankyo.com

SOURCE Daiichi Sankyo Company, Limited